CM-AT Protein Digestion in Autism Clinical Trial Study Posted June 7, 2016 | Comments (1) Call for Participants CM-AT Protein Digestion in Autism Clinical Trial Study The MEND Clinic at Vanderbilt is now enrolling patients in Phase III clinical trials for CM-AT, a treatment for autism. CM-AT is developed by Curemark LLC, a drug research and development company focused on the treatment of neurological diseases. CM-AT is based on Curemark’s recent research that showed enzyme deficiencies in some autistic children result in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. Vanderbilt is one of 25 sites across the country conducting the CM-AT clinical trials. For information on participating in the trial, contact Sarah Marler at (615) 936-3288 or email@example.com. Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window) Related Comments john f | December 13, 2016 at 2:57 pm I would like to read any responses to this study Write a Comment Cancel reply Your email address will not be published. Required fields are marked * Submit Notify me of follow-up comments by email. Notify me of new posts by email.